Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial-Reference-Cited by-同舟云学术

Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial

Published:2016-03 Issue:3 Volume:27 Page:487-493
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Lorusso D.,Scambia G.,Pignata S.,Sorio R.,Amadio G.,Lepori S.,Mosconi A.,Pisano C.,Mangili G.,Maltese G.,Sabbatini R.,Artioli G.,Gamucci T.,Di Napoli M.,Capoluongo E.,Ludovini V.,Raspagliesi F.,Ferrandina G.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/3/487/16699933/mdv608.pdf

Reference26 articles.

1. Integrated genomic analyses of ovarian carcinoma;Cancer Genome Atlas Research Network;Nature,2011

2. Product monograph [database on the Internet] 2010 (10 December 2014, date last accessed).

3. A review of trabectedin (ET-743): a unique mechanism of action;D'Incalci;Mol Cancer Ther,2010

4. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair;Takebayashi;Nat Med,2001

5. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action;Erba;Eur J Cancer,2001

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial;Journal of Clinical Oncology;2024-05-01

2. INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line;British Journal of Cancer;2023-02-09

3. DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities;Cancers;2023-01-10

4. Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case–control study;International Journal of Gynecologic Cancer;2022-12-23

5. Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26);Gynecologic Oncology;2022-12